{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:14:49Z","timestamp":1783401289594,"version":"3.54.6"},"reference-count":79,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Complex percutaneous coronary intervention (PCI) represents a growing proportion of contemporary coronary revascularization, driven by aging populations, increasing comorbidity burden, and advances in interventional techniques. Complex PCI encompasses a spectrum of anatomically and procedurally challenging lesions, including left main disease, bifurcation lesions requiring two-stent strategies, chronic total occlusions, long stent lengths, severe calcification requiring atherectomy, and multivessel revascularization. Antithrombotic therapy, comprising antiplatelet and anticoagulant agents, is essential for preventing stent thrombosis and other ischemic events in both the early and long-term phases after PCI. While antithrombotic therapy mitigates ischemic risks associated with complex PCI, these patients frequently carry a high bleeding risk, thus making the choice of antithrombotic regimen challenging. Recent guideline recommendations emphasize balancing ischemic and bleeding risks rather than relying solely on procedural complexity. This review synthesizes contemporary evidence, guideline recommendations, and clinical considerations for antithrombotic therapy after complex PCI.<\/jats:p>","DOI":"10.3390\/jcm15135196","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:52:24Z","timestamp":1783007544000},"page":"5196","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antithrombotic Strategies After Complex Percutaneous Coronary Intervention"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4630-9815","authenticated-orcid":false,"given":"Yasushi","family":"Ueki","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Shinshu University Hospital, Nagano 390-8621, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2670-7170","authenticated-orcid":false,"given":"Koichiro","family":"Kuwahara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Shinshu University Hospital, Nagano 390-8621, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jcin.2018.12.005","article-title":"Validation of High-Risk Features for Stent-Related Ischemic Events as Endorsed by the 2017 DAPT Guidelines","volume":"12","author":"Ueki","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e402","DOI":"10.4244\/EIJ-D-25-01204","article-title":"Ischaemic and bleeding events after complex versus non-complex PCI: A systematic review and meta-analysis","volume":"22","author":"Piccolo","year":"2026","journal-title":"EuroIntervention"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","article-title":"Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI","volume":"68","author":"Giustino","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijcard.2018.03.103","article-title":"Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation","volume":"268","author":"Genereux","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.jacc.2017.09.011","article-title":"Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention","volume":"70","author":"Yeh","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","first-page":"804","article-title":"Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: Lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4244\/EIJ-D-20-00052","article-title":"Validation of Bleeding Risk Criteria (ARC-HBR) in Patients Undergoing Percutaneous Coronary Intervention and Comparison with Contemporary Bleeding Risk Scores","volume":"16","author":"Ueki","year":"2020","journal-title":"EuroIntervention"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4244\/EIJ-D-20-01197","article-title":"Mortality after bleeding versus myocardial infarction in coronary artery disease: A systematic review and meta-analysis","volume":"17","author":"Piccolo","year":"2021","journal-title":"EuroIntervention"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ueki, Y., Zanchin, T., Losdat, S., Karagiannis, A., Otsuka, T., Siontis, G.C.M., H\u00e4ner, J., Stortecky, S., Pilgrim, T., and Valgimigli, M. (2022). Self-reported non-adherence to P2Y12 inhibitors in patients undergoing percutaneous coronary intervention: Application of the medication non-adherence academic research consortium classification. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0263180"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/S0140-6736(13)61720-1","article-title":"Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study","volume":"382","author":"Mehran","year":"2013","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jacc.2013.11.029","article-title":"Impact of red blood cell transfusion on platelet aggregation and inflammatory response in anemic coronary and noncoronary patients: The TRANSFUSION-2 study (impact of transfusion of red blood cell on platelet activation and aggregation studied with flow cytometry use and light transmission aggregometry)","volume":"63","author":"Silvain","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_14","first-page":"2632","article-title":"Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention: A Consensus Document from the Academic Research Consortium for High Bleeding Risk","volume":"40","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: A pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting","volume":"73","author":"Costa","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients with Chronic Coronary Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"85","author":"Rao","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijcard.2018.08.055","article-title":"Contemporary management of patients referring to cardiologists one to three years from a myocardial infarction: The EYESHOT Post-MI study","volume":"273","author":"Piscione","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ahj.2022.10.006","article-title":"P2Y12 Inhibitors Monotherapy in Patients Undergoing Complex vs Non-Complex Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials","volume":"255","author":"Oliva","year":"2023","journal-title":"Am. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jacc.2022.11.041","article-title":"P2Y(12) Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions","volume":"81","author":"Gragnano","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"855","DOI":"10.5603\/CJ.a2021.0101","article-title":"P2Y12 inhibitor monotherapy in complex percutaneous coronary intervention: A post-hoc analysis of SMART-CHOICE randomized clinical trial","volume":"28","author":"Roh","year":"2021","journal-title":"Cardiol. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jacasi.2022.09.011","article-title":"Clopidogrel Monotherapy After 1-Month DAPT in Patients with High Bleeding Risk or Complex PCI","volume":"3","author":"Yamamoto","year":"2023","journal-title":"JACC Asia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/eurheartj\/ehz453","article-title":"Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: Insights from the Global Leaders trial","volume":"40","author":"Serruys","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.jacc.2020.03.011","article-title":"Ticagrelor with or without Aspirin After Complex PCI","volume":"75","author":"Dangas","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e010812","DOI":"10.1161\/CIRCINTERVENTIONS.121.010812","article-title":"Ticagrelor Monotherapy Versus Ticagrelor with Aspirin in Acute Coronary Syndrome Patients with a High Risk of Ischemic Events","volume":"14","author":"Lee","year":"2021","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jcin.2024.03.017","article-title":"An Aspirin-Free Strategy for Immediate Treatment Following Complex Percutaneous Coronary Intervention","volume":"17","author":"Yamamoto","year":"2024","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e014623","DOI":"10.1161\/CIRCINTERVENTIONS.124.014623","article-title":"Short-Term DAPT After Complex PCI with Third-Generation DES: A Post Hoc Analysis of the HOST-IDEA Trial","volume":"18","author":"Han","year":"2025","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1001\/jamacardio.2022.0052","article-title":"Prasugrel Dose De-escalation Therapy After Complex Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: A Post Hoc Analysis From the HOST-REDUCE-POLYTECH-ACS Trial","volume":"7","author":"Hwang","year":"2022","journal-title":"JAMA Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jamacardio.2023.4587","article-title":"Dual Antiplatelet Therapy De-Escalation in Stabilized Myocardial Infarction with High Ischemic Risk: Post Hoc Analysis of the TALOS-AMI Randomized Clinical Trial","volume":"9","author":"Lee","year":"2024","journal-title":"JAMA Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1093\/eurheartj\/ehaf652","article-title":"Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: The TAILORED-CHIP randomized clinical trial","volume":"47","author":"Kang","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Suruagy-Motta, R.F.O., Tirelli-Rocha, J., Almeida, L.G.S., Aguiar-Barros, A.B.P., Mendes, L.L., Dexheimer da Silva, L., Modi, K., Cox-Alomar, P., de Melo, P.H.M.C., and Filho, E.M. (2026). Duration of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention for bifurcation lesions: A systematic review and meta-analysis. Coron. Artery Dis.","DOI":"10.1097\/MCA.0000000000001648"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy with 12 Months of Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e012004","DOI":"10.1161\/CIRCINTERVENTIONS.122.012004","article-title":"Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort","volume":"15","author":"Obayashi","year":"2022","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e010384","DOI":"10.1161\/CIRCINTERVENTIONS.120.010384","article-title":"Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention: Insight From the STOPDAPT-2 Trial","volume":"14","author":"Yamamoto","year":"2021","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: A multicentre, open-label, randomised superiority trial","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1161\/CIRCULATIONAHA.123.066943","article-title":"Stopping Aspirin within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial","volume":"149","author":"Hong","year":"2024","journal-title":"Circulation"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without Aspirin in High-Risk Patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of Ticagrelor Monotherapy vs Ticagrelor with Aspirin on Major Bleeding and Cardiovascular Events in Patients with Acute Coronary Syndrome: The TICO Randomized Clinical Trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1161\/CIRCULATIONAHA.123.067283","article-title":"Safety and Efficacy of Ticagrelor Monotherapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-Analysis of TWILIGHT and TICO Randomized Trials","volume":"149","author":"Baber","year":"2024","journal-title":"Circulation"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.123.066720","article-title":"An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial","volume":"149","author":"Natsuaki","year":"2024","journal-title":"Circulation"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2Y(12) Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events","volume":"82","author":"Gragnano","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S0140-6736(26)00422-8","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: 10-year follow-up of the HOST-EXAM trial","volume":"407","author":"Kang","year":"2026","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(25)00449-0","article-title":"Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): A randomised, open-label, multicentre trial","volume":"405","author":"Choi","year":"2025","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1093\/eurheartj\/ehae617","article-title":"Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trial","volume":"45","author":"Watanabe","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrcardio.2015.113","article-title":"Switching P2Y12-receptor inhibitors in patients with coronary artery disease","volume":"13","author":"Rollini","year":"2016","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","article-title":"Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): An open-label, blinded-endpoint, randomised controlled superiority trial","volume":"388","author":"Cayla","year":"2016","journal-title":"Lancet"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/eurheartj\/ehac829","article-title":"Dual antiplatelet therapy de-escalation in acute coronary syndrome: An individual patient meta-analysis","volume":"44","author":"Kang","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","article-title":"Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis","volume":"397","author":"Galli","year":"2021","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y(12) Receptor Inhibitor Treatment in Percutaneous Coronary Intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(17)30751-1","article-title":"Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): A double-blind, multicentre, randomised trial","volume":"389","author":"Ohman","year":"2017","journal-title":"Lancet"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1161\/CIRCULATIONAHA.119.044598","article-title":"Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients with Prior Percutaneous Coronary Intervention (COMPASS-PCI)","volume":"141","author":"Bainey","year":"2020","journal-title":"Circulation"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): A randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jcin.2017.11.009","article-title":"Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights from the PIONEER AF-PCI Trial","volume":"11","author":"Kerneis","year":"2018","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e008349","DOI":"10.1161\/CIRCINTERVENTIONS.119.008349","article-title":"Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis from the REDUAL PCI Trial","volume":"13","author":"Berry","year":"2020","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","article-title":"Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials","volume":"40","author":"Gargiulo","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/europace\/euz259","article-title":"Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: Meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials","volume":"22","author":"Potpara","year":"2020","journal-title":"Europace"},{"key":"ref_67","first-page":"E248-60","article-title":"First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the LEADERS all-comers randomized trial","volume":"87","author":"Grundeken","year":"2016","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.4244\/EIJ-D-20-00169","article-title":"Percutaneous coronary intervention for bifurcation coronary lesions: The 15(th) consensus document from the European Bifurcation Club","volume":"16","author":"Burzotta","year":"2021","journal-title":"EuroIntervention"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e005849","DOI":"10.1161\/CIRCINTERVENTIONS.117.005849","article-title":"Benefit of Prolonged Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stent for Coronary Bifurcation Lesions: Results from the Coronary Bifurcation Stenting Registry II","volume":"11","author":"Jang","year":"2018","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.jcin.2018.09.020","article-title":"Dual Antiplatelet Therapy Duration Determines Outcome After 2- But Not 1-Stent Strategy in Left Main Bifurcation Percutaneous Coronary Intervention","volume":"11","author":"Rhee","year":"2018","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijcard.2018.11.139","article-title":"Mid-term outcomes after percutaneous interventions in coronary bifurcations","volume":"283","author":"Zimarino","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"133542","DOI":"10.1016\/j.ijcard.2025.133542","article-title":"Duration of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention for bifurcation lesions: Insights from the ULTRA-BIFURCAT registry","volume":"438","author":"Nebiolo","year":"2025","journal-title":"Int. J. Cardiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.4244\/EIJ-D-21-00514","article-title":"Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: The IDEAL-LM randomised trial","volume":"17","author":"McEntegart","year":"2022","journal-title":"EuroIntervention"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2018.07.084","article-title":"Optimal Duration of Dual Antiplatelet Therapy After Left Main Coronary Stenting","volume":"72","author":"Brener","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e1222-30","DOI":"10.4244\/EIJY15M08_04","article-title":"Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration","volume":"11","author":"Costa","year":"2016","journal-title":"EuroIntervention"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.amjmed.2025.05.038","article-title":"Impact of Dual Antiplatelet Therapy Duration on Long-Term Outcomes Following Chronic Total Occlusion Percutaneous Coronary Intervention","volume":"138","author":"Jiang","year":"2025","journal-title":"Am. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjcard.2020.06.066","article-title":"Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention for Chronic Total Occlusion","volume":"132","author":"Sachdeva","year":"2020","journal-title":"Am. J. Cardiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"164","DOI":"10.15420\/icr.2019.16.R1","article-title":"The Value of Intracoronary Imaging and Coronary Physiology When Treating Calcified Lesions","volume":"14","author":"Ueki","year":"2019","journal-title":"Interv. Cardiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.amjcard.2023.09.070","article-title":"Role of Intravascular Imaging in Complex Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials","volume":"208","author":"Singh","year":"2023","journal-title":"Am. J. Cardiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5196\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:22:54Z","timestamp":1783398174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":79,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15135196"],"URL":"https:\/\/doi.org\/10.3390\/jcm15135196","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]}}}